Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Role of innate and adaptive immunity in obesity-associated metabolic disease
Tracey McLaughlin, … , Lei Shen, Edgar Engleman
Tracey McLaughlin, … , Lei Shen, Edgar Engleman
Published January 3, 2017
Citation Information: J Clin Invest. 2017;127(1):5-13. https://doi.org/10.1172/JCI88876.
View: Text | PDF
Review Series

Role of innate and adaptive immunity in obesity-associated metabolic disease

  • Text
  • PDF
Abstract

Chronic inflammation in adipose tissue, possibly related to adipose cell hypertrophy, hypoxia, and/or intestinal leakage of bacteria and their metabolic products, likely plays a critical role in the development of obesity-associated insulin resistance (IR). Cells of both the innate and adaptive immune system residing in adipose tissues, as well as in the intestine, participate in this process. Thus, M1 macrophages, IFN-γ–secreting Th1 cells, CD8+ T cells, and B cells promote IR, in part through secretion of proinflammatory cytokines. Conversely, eosinophils, Th2 T cells, type 2 innate lymphoid cells, and possibly Foxp3+ Tregs protect against IR through local control of inflammation.

Authors

Tracey McLaughlin, Shelley E. Ackerman, Lei Shen, Edgar Engleman

×

Figure 1

Changes in immune cell content and function in AT in lean versus obese settings influence IR.

Options: View larger image (or click on image) Download as PowerPoint
Changes in immune cell content and function in AT in lean versus obese s...
In lean AT, immune cells play a predominant role in maintaining an antiinflammatory environment. For example, Th2 cells produce antiinflammatory cytokines including IL-4 and IL-10, which promote M2 macrophage polarization, and B cells produce IgM, which produces antiinflammatory IgM. During the course of obesity, significant changes in immune cell content and function occur that promote inflammation. Accumulation of M1 macrophages and Th1 cells results in excess production of proinflammatory cytokines including IFN-γ and TNF-α, and B cells undergo a class-switch, producing IgG.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts